D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nuclear Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.nucmedbio.2014.08.007PMID 25240914PMCID PMC4268387
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling

  2014cited by this paper
• Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments.

  2013cited by this paper
• Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

  2013cited by this paper
• H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.

  2013cited by this paper
• SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.

  2012cited by this paper
• Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

  2012cited by this paper
• Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease

  2011cited by this paper
• Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab.

  2011cited by this paper
• Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention

  2010cited by this paper
• Targeting HER2

  2010cited by this paper
• Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.

  2009cited by this paper
• Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging

  2009cited by this paper
• In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.

  2009cited by this paper
• Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts

  2009cited by this paper
• On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model

  2009cited by this paper
• Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.

  2009cited by this paper
• [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.

  2007cited by this paper
• Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.

  2006cited by this paper
• Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.

  2006cited by this paper
• Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting.

  2006cited by this paper
• Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI).

  2006cited by this paper
• In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.

  2006cited by this paper
• Novel renal amino acid transporters.

  2005cited by this paper
• Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

  2005cited by this paper
• Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

  2004cited by this paper
• Preclinical characterisation of 111In‐DTPA‐trastuzumab

  2004cited by this paper
• Evaluation of cleavable (Tyr3)-octreotate derivatives for longer intracellular probe residence.

  2004cited by this paper
• Polyhedral boron clasters as linkers for attachment of radiohalogens to tumor targeting proteins. II. Radioiodination of monoclonal antibody using potassium [125I]-4-(isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (Iodo-DABI)

  2003cited by this paper
• N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs.

  2003cited by this paper
• Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

  2002cited by this paper
• A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).

  2001cited by this paper
• Targeting HER2 in other tumor types.

  2001cited by this paper
• Clinical trials of Herceptin(trastuzumab).

  2001cited by this paper
• Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.

  2000cited by this paper
• The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels.

  1994cited by this paper
• Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells.

  1991cited by this paper
• N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination.

  1991cited by this paper
• Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents.

  1990cited by this paper
• A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine.

  1987cited by this paper

• Evaluation of Dynamic Light Scattering as an Effective Quality Control Method for Aggregates in Radiolabeled Antibodies.

  2024cites this paper
• Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.

  2022cites this paper
• Examination of the impact molecular charge has on NTSR1-targeted agents incorporated with cysteine protease inhibitors.

  2022cites this paper
• Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.

  2020cites this paper
• Solid scintillation analysis

  2020cites this paper
• Efficient 125I-radiolabeling of biomolecules using a strain-promoted oxidation-controlled cyclooctyne-1,2-quinone cycloaddition reaction.

  2019cites this paper
• The Radiopharmaceutical Chemistry of the Radioisotopes of Iodine

  2019cites this paper
• Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab

  2019cites this paper
• Understanding the In Vivo Fate of Radioimmunoconjugates for PET and SPECT

  2019cites this paper
• d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution

  2018influential citation
• Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

  2018cites this paper
• Synthesis and Development of Diagnostic Tools for Medical Imaging

  2017cites this paper